Acadian Asset Management
LYEL icon

Acadian Asset Management’s Lyell Immunopharma LYEL Stock Holding History

Acadian Asset Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,657
Closed -$51K – 2158
2025
Q4 		$51K Sell
1,657
-9,733
-85% -$218K ﹤0.01% 1790
2025
Q3 		$184K Sell
11,390
-15,976
-58% -$182K ﹤0.01% 1415
2025
Q2 		$241K Sell
27,366
-5,679
-17% -$51.7K ﹤0.01% 1276
2025
Q1 		$354K Buy
33,045
+22,181
+204% +$272K ﹤0.01% 1146
2024
Q4 		$139K Buy
+10,864
New +$215K ﹤0.01% 1312
2024
Q2 		– Sell
-3,898
Closed -$173K – 1846
2024
Q1 		$173K Buy
+3,898
New +$167K ﹤0.01% 1205

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
GP
GSK plc London $599M AUM
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $271M AUM 309.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Acadian Asset Management's LYEL Position: Q1 2026 in Review

Acadian Asset Management sold out of Lyell Immunopharma (LYEL) in Q1 2026, closing a stake of 1,657 shares — an estimated $51K sold.

Acadian Asset Management first reported a position in LYEL in Q1 2024 and held it in 6 quarters. The position peaked at $354K in Q1 2025. 74 funds tracked by Wall St. Rank hold LYEL as of Q1 2026.

  • Acadian Asset Management reported no remaining Lyell Immunopharma position as of Q1 2026 after selling out during the quarter.
  • Acadian Asset Management sold 1,657 Lyell Immunopharma shares in Q1 2026, an estimated $51K.
  • Acadian Asset Management first reported a position in Lyell Immunopharma in Q1 2024 and held it in 6 quarters.
  • Acadian Asset Management's Lyell Immunopharma position peaked at $354K in Q1 2025.
  • 74 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.